Gilead Connecticut, Inc.

Gilead Sciences, Inc.

Cgi Pharmaceuticals, Inc.

Neurogen Corporation

Genentech, Inc.

Kronos Bio, Inc.

Novartis International Pharmaceutical, Ltd.

Genetech, Inc.

Nurix Therapeutics, Inc.

Cellular Genomics, Inc.

Pfizer Corporation

Scott A Mitchell

Kevin S Currie

Peter A Blomgren

Seung H Lee

Jeffrey E Kropf

Jianjun Xu

Zhongdong Zhao

Aaron C Schmitt

Jennifer R Lo

Sundaramoorthi Swaminathan

Douglas Gregory Stafford

Pavel E Zhichkin

Robert W DeSimone

Jayaraman Chandrasekhar

Jin-Ming Xiong

James William Darrow

Douglas A Pippin

Jeff A Zablocki

George D Maynard

Rao V Kalla

Thao Perry

Julian Andrew Codelli

John H Conway

Jun Yuan

Gary Bruce Phillips

He Zhao

Xiaojing Wang

Daniel Fred Ortwine

Wendy B Young

Musong Kim

Suet Chung Yeung

Kyungae Lee

Mark J Bartlett

Joshua J Van Veldhuizen

Gayatri Balan

Manuka Ghosh

Jennifer Alissa Loyer-Drew

Antonio J M Barbosa

Patrick J Salvo

Alan J Hutchison

William John Watkins

Chandrasekar Venkataramani

Juan A Guerrero

Zhimin Du

David R Brittelli

Jennifer Leigh Cosman

Honglu Zhang

Ravi Krishnamoorthy

Pamela Ann Albaugh

David M Armistead

George P Luke

Mihaela Diana Danca

Guiying Li

Nian Liu

Zachary A Kasun

Antonio J M Barbosa, Jr

Soumya Mitra

James P Harding

John O Link

Hyung-Jung Pyun

Scott E Lazerwith

Zheng-Yu Yang

Peiyuan Wang

Darryl Kato

Barton W Phillips

Sheila M Zipfel

Gregory Notte

Devan Naduthambi

Linda M Gustavson

Guolin Cai

Matthew Ernst Voss

Jiayao Li

Joshua A Kaplan

Samuel E Metobo

Adam James Schrier

Michael Sangi

Ashley Anne Katana

Kirk L Stevens

Spiros Liras

Evangelos Aktoudianakis

Julie Farand

Qin Guo

Martin Patrick Allen

Julie A Di Paolo

Astrid Clarke

Yang Gao

John Edward Knox, Jr

Linghong Xie

Scott Preston Simonovich

Christopher Allen Ziebenhaus

Kristyna M Elbel

Antonio J Barbosa

Andrew Y Thurkauf

Bingsong Han

Bertrand Leo Chenard

John M Peterson

Hunter Paul Shunatona

John Buell

Joseph Raker

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2:

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor

The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

Substituted 6-azabenzimidazole compounds

The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

Substituted eneoxindoles and uses thereof

The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.

Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2: 

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

Certain imidazopyridines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

Imidazopyridines Syk inhibitors

Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyridone and aza-pyridone compounds and methods of use

The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R, R, R, and Rare as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

Substituted imidazo[1,2-a]pyrazines as Syk inhibitors

Compounds having the following formula (I) and methods of their use and preparation are disclosed: 

Tank-binding kinase inhibitor compounds

Growing community of inventors

East Haven, CT, United States of America

Scott A Mitchell